Combination Treatment for Glioblastoma Cells with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Oncolytic Adenovirus Delta-24. (1st November 2013)

• Record Type: Journal Article
• Authors: Tsamis, Konstantinos I.; Alexiou, George A.; Vartholomatos, Evrysthenis; Kyritsis, Athanasios P.
• Is Part Of: Cancer investigation. Volume 31:Number 9(2013)
• Page Start: 630
• Page End: 638
• Publication Date: 2013-11-01
• Subjects: Adenovirus -- Apoptosis -- Caspase -- Delta-24 -- Glioblastoma -- TRAIL; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2013.849724
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract : Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exhibits cancer-selective killing activity representing a promising anticancer therapeutic strategy. Adenovirus Delta-24 is another interested anticancer agent selectively killing cells with a defective p16/Rb/E2F pathway. However, many types of cancer, including gliomas, could develop resistance to Delta-24 or TRAIL-induced apoptosis. In this study, we investigated whether TRAIL, in combination with adenovirus Delta-24, could result in an enhanced antiglioma effect in vitro in a panel of glioblastoma cell lines (U87MG, U251MG, D54, and T98G). The treatment of glioblastoma cell lines with TRAIL and Delta-24 adenovirus in combination showed markedly enhanced effect, compared to each agent alone.